NCT02640807View on ClinicalTrials.gov

A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

August 27, 2018

Study Completion Date

August 27, 2018

Conditions
Severe Sepsis With Septic Shock
Interventions
DRUG

Interleukin-7

IM (intra-muscular) administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR (International Normalized Ratio) \>2.5 or platelet count \< 35,000

DRUG

Placebo

IM administration of Placebo (SC administration for patients with INR\>2.5 or platelet count \< 35,000

Trial Locations (1)

37212-1050

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
collaborator

Vanderbilt University School of Medicine

OTHER

collaborator

Washington University School of Medicine

OTHER

lead

Revimmune

INDUSTRY

NCT02640807 - A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients | Biotech Hunter | Biotech Hunter